

ARDEA BIOSCIENCES LIMITED

Directors' Report and Financial Statements

Registered number 06519375

31 December 2019



Directors' Report and Financial Statements

Contents	Page
Directors' Report	2
Statement of Directors' Responsibilities in respect of the Directors' Report and the Financial Statements	3
Balance Sheet	4
Accounting Policies	5
Notes to the Financial Statements	6

Directors Matthew Bowden (appointed 27 February 2019)
Katie Jackson-Turner (resigned 27 February 2019)
Adrian Charles Noel Kemp

Registered Office 1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
United Kingdom

Date 26 August 2020

DIRECTORS' REPORT 2019

The Directors of Ardea Biosciences Limited (the "**Company**") present their Report, together with the Financial Statements of the Company, for the year ended 31 December 2019.

Review of Business

In January 2008 the decision was taken to cease the principal business activity of provision of consultancy services to healthcare organisations in the UK.

The Company did not trade during the year under review and does not plan to do so during 2020.

Directors

The Directors whose names appear at the head of this Report were Directors of the Company, unless otherwise noted, at the date of this Report and for the whole of the period under review.

Auditors

The Company being dormant within the meaning of Section 480(1) of the Companies Act 2006 is entitled to exemption under that provision, and no Auditor will be appointed.

On behalf of the Board

DocuSigned by:
Adrian Kemp
903B28E62188466...
Adrian Kemp
Director

STATEMENT OF DIRECTORS' RESPONSIBILITIES IN RESPECT OF THE DIRECTORS' REPORT AND THE FINANCIAL STATEMENTS

The Directors are responsible for preparing the Directors' Report and the Financial Statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare Financial Statements for each financial year. Under that law they have elected to prepare the Financial Statements in accordance with UK Accounting Standards and applicable law (UK Generally Accepted Accounting Practice) including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* ("**FRS 102**").

Under company law the Directors must not approve the Financial Statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these Financial Statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the Financial Statements; and
- prepare the Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue in the business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the Financial Statements comply with the Companies Act 2006. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities.

BALANCE SHEET

At 31 December

	Notes	2019 £	2018 £
Current assets			
Debtors	3	1	1
Net assets		1	1
Capital and reserves			
Called-up share capital	4	1	1
Total shareholder's funds	5	1	1

- (a) For the year ended 31 December 2019 the Company was entitled to exemption under subsections (1) and (2) of Section 480 of the Companies Act 2006.
- (b) Members have not required the Company to obtain an audit in accordance with Section 476 of the Companies Act 2006.
- (c) The Directors acknowledge their responsibility for:
- (i) ensuring the Company keeps accounting records which comply with Section 386; and
 - (ii) preparing accounts which give a true and fair view of the state of affairs of the Company as at the end of the financial year, and of its profit and loss for the financial year, in accordance with the requirements of Sections 393 and 394, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the Company.

The accounting policies on page 5 and the Notes to the Financial Statements on page 6 form part of these Financial Statements.

The Financial Statements were approved by the Board of Directors on 26 August 2020 and were signed on its behalf by:

DocuSigned by:
Adrian Kemp
903B28E62188466...
Adrian Kemp
Director

ACCOUNTING POLICIES

Basis of accounting

The Company is a limited liability company incorporated and domiciled in England and Wales.

These financial statements were prepared in accordance with Financial Reporting Standard 102. As the Company has met the Companies Act 2006 definition of a dormant company as at and since the date of transition the accounting policies applied at the date of transition under previous GAAP have been retained as permitted by paragraph 10(m) of chapter 35 of FRS 102.

No profit and loss account is presented with these financial statements because the Company has not received income, incurred expenditure or recognised any gains or losses during either the period under review or the preceding financial year. No statement of changes in equity is presented with these financial statements because there have been no movement in shareholder's funds during either the period under review or the preceding financial year.

Under FRS 102 the Company is exempt from the requirement to prepare a cash flow statement on the grounds that the ultimate parent undertaking, AstraZeneca PLC, includes the Company in its own published consolidated Financial Statements. AstraZeneca PLC's consolidated Financial Statements is available online on the website www.astrazeneca.com or can be obtained from the address given in Note 6.

NOTES TO THE FINANCIAL STATEMENTS

1. Emoluments of Directors

None of the Directors received any emoluments in respect of their services to the Company in the year (2018: nil).

2. Employee costs

The Company employed no staff during the year (2018: nil).

3. Debtors

	2019	2018
	£	£
Due after more than one year:		
Amounts owed by group undertakings	1	1

4. Called-up share capital

	2019	2018
	£	£
Allotted, called-up and fully paid:		
One ordinary share of £1	1	1

5. Reconciliation of movements in shareholder's funds

	2019	2018
	£	£
At 1 January and 31 December	1	1

6. Ultimate parent company and parent undertaking of larger group of which the Company is a member

The Company is a subsidiary undertaking of Ardea Biosciences, Inc., a company incorporated in the USA. The Directors consider AstraZeneca PLC, a company incorporated in England and Wales, to be the ultimate parent company.

The smallest and largest group in which the results of the Company are consolidated is that headed by AstraZeneca PLC, who is the ultimate controlling party. The consolidated accounts of this group are available to the public online and may be obtained from the registered office, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom.